The costs of conducting clinical research

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4145-4150

  Emanuel, Ezekiel J ^a   Schnipper, Lowell E ^a   Kamin, Deborah Y ^a   Levinson, Jenifer ^a   Lichter, Allen S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLACEBO;

CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG INDUSTRY; GOVERNMENT; HEALTH CARE COST; HUMAN; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; ARTICLE; COST; ECONOMICS; FINANCIAL MANAGEMENT; MEDICAL RESEARCH; MULTICENTER STUDY; NEOPLASM; PHARMACOECONOMICS; PHASE 3 CLINICAL TRIAL;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS, PHASE III; COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; FINANCING, GOVERNMENT; HEALTH CARE COSTS; HUMANS; MULTICENTER STUDIES; NEOPLASMS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS;

EID: 0642316794     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.156     Document Type: Review

References (6)

1. National Institutes of Health Office of Extramural Research: http:// grants.nih.gov/grants/policy/emprograms/overview/ep-coi.htm
2. Spiro HM: Mammon and medicine: The rewards of clinical trials. JAMA 255:1174-1175, 1986
3. Lind SE: Finder's fees for research subjects. N Engl J Med 323:192-195, 1990
4. Shimm DS, Spece RG: Industry reimbursement for entering patients into clinical trials: Legal and ethical issues. Ann Intern Med 115:148-151, 1991
5. Lind SE: Financial issues and incentives related to clinical research and innovative therapies, in HY Vanderpool (ed): The Ethics of Research Involving Human Subjects: Facing the 21st Century. Frederick, MD, University Publishing Group, 1996, pp 185-202
6. Eichenwald K, Kolata G: Drug trials hide conflicts for doctors. New York Times, May 16, 1999, A1, A28